UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 4, 2005
Arena Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
000-31161 |
|
23-2908305 |
|
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
of Incorporation) |
|
|
|
Identification No.) |
|
|
|
|
|
|
|
6166 Nancy Ridge Drive, San Diego, California 92121 |
||||
|
(Address of Principal Executive Offices) (Zip Code) |
||||
|
|
|
|
|
|
|
(858) 453-7200 |
||||
|
(Registrant’s telephone number, including area code) |
||||
|
|
|
|
|
|
|
N/A |
||||
|
(Former Name or Former Address, if Changed Since Last Report) |
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On May 4, 2005, Arena Pharmaceuticals, Inc. was granted patent number 03 718 323, entitled “5-HT2C Receptor Modulators,” by the European Patent Office. The patent relates to novel compounds that modulate the 5-HT2C serotonin receptor, which is thought to be involved in the regulation of food intake and may be useful in pharmaceutical compositions for the treatment of obesity. APD356, discovered by Arena, is an orally available 5-HT2C receptor modulator covered under the patent. Arena intends to validate the patent in 31 European jurisdictions, including Germany, France, Italy, the United Kingdom and Spain, as well as Hong Kong.
Forward-Looking Statements
Certain statements in this Form 8-K are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the 5-HT2C serotonin receptor’s profile and pharmaceutical behavior and Arena’s intention to validate the European patent covering APD356. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the success of Arena’s research and clinical studies and Arena’s ability to obtain and defend its patents. Additional factors that could cause actual results to differ materially from those stated or implied by Arena’s forward-looking statements are disclosed in Arena’s filings with the Securities and Exchange Commission. These forward-looking statements represent Arena’s judgment as of the time of the filing of this Form 8-K. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: May 5, 2005 |
Arena Pharmaceuticals, Inc., |
||
|
|
a Delaware corporation |
||
|
|
|
||
|
|
|
||
|
|
By: |
/s/ Jack Lief |
|
|
|
|
Jack Lief |
|
|
|
|
President and Chief Executive Officer |
|
2